Literature DB >> 3101503

Induction of hepatic veno-occlusive disease in dogs.

H M Shulman, K Luk, H J Deeg, W B Shuman, R Storb.   

Abstract

The authors attempted to induce hepatic veno-occlusive disease (VOD) in 64 dogs. Preparative treatments included combinations of total-body irradiation (TBI) or localized hepatic irradiation (LI) or both and chemotherapy consisting of dimethylbusulfan (DMB), L-phenylalanine mustard (L-PAM), methotrexate, or monocrotaline. VOD occurred infrequently in those dogs given 9.2 Gy TBI and DMB (1/10), TBI and/or LI (9.2-27 Gy) with L-PAM (2/36) or high dose methotrexate and LI (0/2). Specifically, VOD occurred in the dogs with a shorter interval between TBI and DMB or in the dog that received the glutathione reductase inhibitor, buthionine sulfoximide (BSO) before L-PAM. In contrast, among 17 dogs given monocrotaline, 8 developed VOD, particularly when used with L-PAM +/- irradiation (7/13). The major cause of death, early gastrointestinal toxicity, was further augmented by higher doses of irradiation, by shortening the interval between LI and L-PAM administration to less than 4 weeks, and administering BSO or monocrotaline before L-PAM. Gastrointestinal toxicity was lessened by giving low dose cyclophosphamide given before L-PAM. VOD can be produced in dogs especially with monocrotaline or BSO given before and L-PAM +/- irradiation. However, gastrointestinal toxicity renders the study of VOD beyond the acute phase difficult. Nevertheless, this approach appears useful for the study of VOD in other animals and for developing agents aimed at preventing VOD.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3101503      PMCID: PMC1899548     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

1.  Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems.

Authors:  M Nesbit; W Krivit; R Heyn; H Sharp
Journal:  Cancer       Date:  1976-02       Impact factor: 6.860

2.  Dimethyl myleran and autologous marrow grafting for the treatment of spontaneous canine lymphoma.

Authors:  P L Weiden; R Storb; H Shulman; T C Graham
Journal:  Eur J Cancer       Date:  1977-12       Impact factor: 9.162

3.  Effects of fractionated doses of fast neutrons and photons on the normal canine lung: relative biological effectiveness values obtained by radionuclide studies.

Authors:  E W Bradley; P O Alderson; J A Deye; K G Mendenhall; M P Fisher; F Vieras; C C Rogers
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979-02       Impact factor: 7.038

4.  Immunologic, toxicologic and marrow transplantation studies in dogs given dimethyl myleran.

Authors:  H J Kolb; R Storb; P L Weiden; H D Ochs; H Kolb; T C Graham; G L Floersheim; E D Thomas
Journal:  Biomedicine       Date:  1974-09

Review 5.  The toxic actions of pyrrolizidine (senecio) alkaloids.

Authors:  E K McLean
Journal:  Pharmacol Rev       Date:  1970-12       Impact factor: 25.468

6.  Marrow infusions in dogs given midlethal or lethal irradiation.

Authors:  E D Thomas; R LeBlond; T Graham; R Storb
Journal:  Radiat Res       Date:  1970-01       Impact factor: 2.841

7.  Studies on the cytotoxicity of Myleran and dimethyl Myleran.

Authors:  M P Mitchell; I G Walker
Journal:  Can J Biochem       Date:  1972-10

8.  Hepatic veins of monkeys with veno-occlusive disease. Sequential ultrastructural changes.

Authors:  J R Allen; L A Carstens; G J Katagiri
Journal:  Arch Pathol       Date:  1969-03

9.  Cyclophosphamide pretreatment reduces the toxic effect of high dose melphalan on intestinal epithelium in sheep.

Authors:  J L Millar; T A Phelps; R L Carter; T J McElwain
Journal:  Eur J Cancer       Date:  1978-11       Impact factor: 9.162

Review 10.  The clinical pharmacology of methotrexate: new applications of an old drug.

Authors:  W A Bleyer
Journal:  Cancer       Date:  1978-01       Impact factor: 6.860

View more
  7 in total

Review 1.  A Critical Analysis of Experimental Animal Models of Sinusoidal Obstruction Syndrome.

Authors:  Arvind Kumar; Richard Palek; Vaclav Liska
Journal:  J Clin Exp Hepatol       Date:  2018-07-17

2.  Multiple acquired extrahepatic portosystemic shunts secondary to veno-occlusive disease in a young German shepherd.

Authors:  Dan Fredholm
Journal:  Can Vet J       Date:  2009-07       Impact factor: 1.008

Review 3.  Sinusoidal obstruction syndrome (hepatic veno-occlusive disease).

Authors:  Cathy Q Fan; James M Crawford
Journal:  J Clin Exp Hepatol       Date:  2014-10-30

4.  Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation.

Authors:  G Vassal; S Koscielny; D Challine; D Valteau-Couanet; I Boland; A Deroussent; J Lemerle; A Gouyette; O Hartmann
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

5.  Feasibility of non-TBI conditioning with busulfan and fludarabine for allogeneic stem cell transplantation in lymphoid malignancy.

Authors:  Ho Cheol Shin; Yoo Jin Lee; Joon Ho Moon; Soo Jung Lee; Byung Woog Kang; Yee Soo Chae; Jong Gwang Kim; Jun Young Choi; Jong Won Seo; Yu Kyung Kim; Jang Soo Suh; Sang Kyun Sohn
Journal:  Korean J Intern Med       Date:  2012-02-28       Impact factor: 2.884

Review 6.  Radiation-induced liver disease: current understanding and future perspectives.

Authors:  Jieun Kim; Youngmi Jung
Journal:  Exp Mol Med       Date:  2017-07-21       Impact factor: 8.718

7.  Idiopathic hepatic veno-occlusive disease causing Budd-Chiari-like syndrome in a cat.

Authors:  T A Cave; H Martineau; A Dickie; H Thompson; D J Argyle
Journal:  J Small Anim Pract       Date:  2002-09       Impact factor: 1.522

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.